Use of newer anticoagulants in patients with chronic kidney disease

American Journal of Health-System Pharmacy

Volumn 64, Issue 19, 2007, Pages 2017-2026

  Lobo, Bob L ^a,b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticoagulants; Argatroban; Dosage; Excretion; Fondaparinux; Heparin; Heparins; Kidney failure; Thromboembolism; Toxicity

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; IDRAPARINUX; IPRIVASK; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG; THROMBIN INHIBITOR; TINZAPARIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BOLUS INJECTION; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INDICATION; DRUG INFORMATION; HUMAN; KIDNEY FUNCTION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 34948878144     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060673     Document Type: Review

References (54)

1. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs. 2005; 5:291-305.
2. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: Chest. 2004; 126(3 suppl):338S-400S.
3. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment. Chest. 2004; 126(3 suppl):287S-310S.
4. Koo S, Kucher N, Nguyen PL et al. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med. 2004;164:1557-60.
5. Han JH, Chandra A, Mulgund J et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med. 2006;119:248-54.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2, suppl 1):S1-266.
7. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41:1-12.
8. Stevens LA, Coresh J, Greene T et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354:2473-83.
9. Creatinine standardization program recommendations for pharmacists and authorized drug prescribers. Vol. 2007. Bethesda, MD: National Kidney Disease Education Program; 2006.
10. Cantu TG, Ellerbeck EF, Yun SW et al. Drug prescribing for patients with changing renal function. Am J Hosp Pharm. 1992; 49:2944-8.
11. Macie C, Forbes L, Foster GA et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004; 125:1616-21.
12. Schmid P, Fischer A, Wuillemin W. Prevalence of impaired renal function and use of anticoagulants in medical inpatients. Paper presented at 50th annual meeting of the Society for Research on Thrombosis and Haemostaseology. Basel, Switzerland; 2006.
13. Corsonello A, Pedone C, Corica F et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005; 165:790-5.
14. D'souza G, Parvizi J, Jun J. A retrospective study of creatinine clearance in postoperative total joint replacement patients in the geriatric age group . . . a word of caution with the use of enoxaparin. Anesth Analg. 2006; 102(suppl 1):S-321. Abstract.
15. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am. 2005; 89:649-87.
16. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood. 1999; 94:2569-74.
17. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure. West J Med. 1992; 156:633-8.
18. Hulot JS, Montalescot G, Lechat P et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther. 2005; 77:542-52.
19. GlaxoSmithKline. Arixtra (fondaparinux sodium [injection]) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2005 Oct.
20. Nutescu EA, Shapiro NL, Chevalier A et al. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med. 2005; 72(suppl 1):S2-6.
21. Fragmin (dalteparin sodium injection) prescribing information. New York: Pfizer; 2006 Oct.
22. Innohep (tinzaparin sodium injection) prescribing information. Boulder, CO: Pharmion Corporation; 2007 Jan.
23. Lovenox (enoxaparin sodium injection) prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2006 Sep.
24. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin; the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S-203S.
25. Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med. 2005; 72(suppl 1):S37-42.
26. Preparing for the post-warfarin generation of antithrombotics. Am J Manag Care. 2004; 10(10 suppl):S318-23.
27. Iprivask (desirudin for injection) prescribing information. Bridgewater, NJ: Aventis Pharmaceuticals; 2003.
28. Refludan (lepirudin [rDNA] for injection) prescribing information. Wayne, NJ: Bayer Healthcare Pharmaceuticals; 2006 Nov.
29. Argatroban prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2005 Jul.
30. Antman E. The re-emergence of anticoagulation in coronary disease. Eur Heart J. 2004; 6(suppl B):B2-8.
31. Katsouras C, Michalis LK, Papamichael N et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J. 2005; 150:385-91.
32. Angiomax (bivalirudin for injection) prescribing information. Parsippany, NJ: Medicines Company; 2005 Dec.
33. Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354:1464-76.
34. Walker CP, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth. 2002; 88:848-63.
35. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-29.
36. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2006;22:169-76.
37. Murray PT, Reddy BV, Grossman EJ et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004; 66:2446-53.
38. Reddy BV, Grossman EJ, Trevino SA et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005; 39:1601-5.
39. Tang IY, Cox DS, Patel K et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39:231-6.
40. Lim W, Dentali F, Eikelboom JW et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006; 144:673-84.
41. Fox KA, Bassand JP, Wallentin L et al. The efficacy and safety of fondaparinux versus enoxaparin in non-ST elevation ACS: impact of renal dysfunction (OASIS 5). Paper presented at 55th annual scientific session of the American College of Cardiology. Atlanta, GA; 2006.
42. Spinler SA, Inverso SM, Cohen M et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI HB studies. Am Heart J. 2003; 146:33-41.
43. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000; 12(suppl F):33F-36F.
44. Rabbat CG, Cook DJ, Crowther MA et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005;20:357-63.
45. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002; 162:2605-9.
46. Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost. 2005;3:2593-6.
47. Tardy B, Lecompte T, Boelhen F et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006; 108:1492-6.
48. Greinacher A. Treatment options for heparin-induced thrombocytopenia. Am J Health-Syst Pharm. 2003; 60(suppl 5):S12-8.
49. Montalescot G, Collet JP, Tanguy ML et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004; 110:392-8.
50. Laposata M. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
51. Bazinet A, Almanric K, Brunet C et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005; 116:41-50.
52. Chow SL, Zammit K, West K et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003; 43:586-90.
53. Sanderink GJ, Guimart CG, Ozoux ML et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225-31.
54. GlaxoSmithKline. Medical Information Letter. Use of Arixtra in patients with renal impairment. Philadelphia, PA; 2006 May.